indatuximab ravtansine (BT-062) / ImmunoGen, Grifols, ADMA Biologics  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
indatuximab ravtansine (BT-062) / Grifols
NCT00723359: Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

Completed
1
32
US
BT062
Biotest Pharmaceuticals Corporation, Biotest
Multiple Myeloma
04/12
04/12

Download Options